Aktiengesellschaft Bayer Gl... Net Worth

The estimated Net Worth of Aktiengesellschaft Bayer Gl... is at least $256 Million dollars as of 5 January 2018. Aktiengesellschaft Gl owns over 527,472 units of CRISPR Therapeutics AG stock worth over $255,954,523 and over the last 7 years Aktiengesellschaft sold CRSP stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Aktiengesellschaft Gl CRSP stock SEC Form 4 insiders trading

Aktiengesellschaft has made over 1 trades of the CRISPR Therapeutics AG stock since 2018, according to the Form 4 filled with the SEC. Most recently Aktiengesellschaft bought 527,472 units of CRSP stock worth $11,999,988 on 5 January 2018.

The largest trade Aktiengesellschaft's ever made was buying 527,472 units of CRISPR Therapeutics AG stock on 5 January 2018 worth over $11,999,988. On average, Aktiengesellschaft trades about 527,472 units every 0 days since 2018. As of 5 January 2018 Aktiengesellschaft still owns at least 5,632,802 units of CRISPR Therapeutics AG stock.

You can see the complete history of Aktiengesellschaft Gl stock trades at the bottom of the page.

What's Aktiengesellschaft Gl's mailing address?

Aktiengesellschaft's mailing address filed with the SEC is KAISER WILHEM ALLEEENERGIEWEG 1, 3641 RT, , LEVERKUSENMIJDRECHT, 2MP7, 51368.

Insiders trading at CRISPR Therapeutics AG

Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani, and Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Complete history of Aktiengesellschaft Gl stock trades at CRISPR Therapeutics AG

CRISPR Therapeutics AG executives and stock owners

CRISPR Therapeutics AG executives and other stock owners filed with the SEC include:

• Samarth Kulkarni,
  Chief Executive Officer, Director
• Lawrence Klein,
  Chief Operating Officer, Chief Business Officer
• Tony Ho,
  Executive Vice President - Research and Development
• James Kasinger,
  General Counsel, Secretary
• Michael Tomsicek,
  Chief Financial Officer
• Dr. Samarth Kulkarni,
  CEO & Director
• Dr. Lawrence Otto Klein Ph.D.,
  Chief Operating Officer
• James R. Kasinger,
  Gen. Counsel & Sec.
• Rodger Novak,
  Chairman of the Board, President, Co-Founder
• Dr. Rodger Novak M.D.,
  Founder, Chairman & Pres
• Susan Kim,
  IR Contact Officer
• Katherine High,
  Independent Director
• John Greene,
  Independent Director
• Simeon George,
  Independent Director
• Bradley Bolzon,
  Independent Director
• Ali Behbahani,
  Independent Director
• Dr. Daniel G. Anderson Ph.D.,
  Scientific Founder & Advisory Board Member
• Dr. Matthew Porteus M.D., Ph.D.,
  Scientific Founder & Advisory Board Member
• Dr. Chad Cowan Ph.D.,
  Scientific Founder
• Dr. Craig C. Mello Ph.D.,
  Scientific Founder & Advisory Board Member
• Dr. Emmanuelle Marie Charpentier,
  Co-Founder & Scientific Advisory Board Member
• Shaun Foy,
  Founder
• Aktiengesellschaft Bayer Gl...,
  
• Tyler Dylan Hyde,
  Chief Legal Officer
• Pablo J Cagnoni,
  Director
• Venture Capital Iv, L.P.Ver...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Kurt Von Emster,
  Director
• Sven Ante Lundberg,
  Chief Scientific Officer
• Corp /De/ Celgene,
  10% owner
• Kala Subramanian,
  See Remarks
• Thomas Woiwode,
  Director
• N Anthony Coles,
  Director
• Plc Gsk,
  10% owner
• Pharmaceuticals (Europe) Lt...,
  
• Venture Capital Iv, L.P.Ver...,
  
• Julianne Bruno,
  Chief Operating Officer
• Brendan Smith,
  Chief Financial Officer
• Venture Capital Iv, L.P.Ver...,
  
• Venture Capital V, L.P.Vers...,
  
• Naimish Patel,
  Chief Medical Officer
• Harold Edward Fleming,
  
• Maria Fardis,
  
• Sandesh Mahatme,
  
• Douglas A Treco,
  
• Christian Rommel,
  
• Phuong Khanh Morrow,
  Chief Medical Officer
• Raju Prasad,
  Chief Financial Officer